During the past decade, Orel Oncology Center conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 1 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Orel Oncology Center" are "Adenocarcinoma of the Lung" (1 trials), "Breast Cancer With Low to Intermediate HER2 Expression" (1 trials), "Non-small-cell Lung Cancer" (1 trials), "Prostate Cancer Metastatic" (1 trials) and "Small Cell Lung Cancer" (1 trials). Many other conditions were trialed in "Orel Oncology Center" in a lesser frequency.

Most popular intervention types in "Orel Oncology Center" are "Drug" (3 trials), "Biological" (2 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "AXL1717" (1 trials), "Docetaxel" (1 trials), "GM-CSF" (1 trials), "GM-CSF Placebo" (1 trials) and "Leukine® (sargramostim, GM-CSF) and water for injection" (1 trials). Other intervention names were less common.

The vast majority of trials in "Orel Oncology Center" are 2 trials for "All" genders, 1 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Orel Oncology Center". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Orel Oncology Center, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Orel Oncology Center, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".